ClinicalTrials.gg
Status unknownNCT04414852Updated Jun 4, 2020

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

A Phase 1 interventional study of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-04.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Other

The sponsor has not verified this record recently (last verified Jun 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The primary objective of the study is to compare the pharmacokinetics of apatinib in subjects with impaired renal function and healthy subjects, to give dose recommendations for patients with impaired renal function.

02

Conditions studied

  • Subjects With Impaired Renal Function and Healthy Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

for subjects with impaired renal function

  • Able to comprehend and willing to sign an form (ICF)
  • 18-70 years of age.
  • 19 kg/m2\< \<19-28 kg/m2
  • (MDRD equation) for mild impaired renal function: 60-89 mL/min/1.73 m2 eGFR (MDRD equation) for moderate impaired renal function: 30-59 mL/min/1.73 m2
  • In good health, except for kidney disease and complications, determined by no findings from medical history, physical examination, 12-lead ;
  • Agree to take approved method of during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;

for healthy subjects:

  • Able to comprehend and willing to sign an informed consent form (ICF)
  • 18-70 years of age.
  • 19 kg/m2\<BMI \<19-28 kg/m2
  • eGFR (MDRD equation) for mild impaired renal function: ≥90mL/min/1.73 m2
  • In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG;
  • Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;

Exclusion criteria

Exclusion Criteria:

for subjects with renal impairment

  • Renal allograft recipients;
  • Need hemodialysis during study;
  • Uroclepsia or anuria;
  • Allergic to apatinib or ingredients;
  • History of heart disease in 12 months before study;
  • Coagulation disorders;
  • Hypertension and could not be controlled with hypotensor;
  • With hepatic or archenteric disease;
  • Participate in blood donation within 3 months before screening and donate blood volume ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month prior dosing.
  • Take any clinical trial drugs within 3 months prior dosing;
  • Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days before dosing;
  • Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit = 285 mL of beer, or 100mL of wine), or take ≥5 cigarettes;
  • Positive in urine drug test;
  • Combined with other viral infections (anti-, anti- positive, positive) or combined with syphilis infection;
  • Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or grapefruit-containing products from 48 hours before dosing to the end of the study;
  • The investigator believes that the subjects are not eligible to participate in this trial.

for healthy subjects:

  • Renal allograft recipients;
  • Allergic to apatinib or ingredients;
  • History of heart disease in 12 months before study;
  • Coagulation disorders;
  • Hypertension and could not be controlled with hypotensor;
  • With hepatic or archenteric disease;
  • Participate in blood donation within 3 months before screening and donate blood volume ≥400mL, or receive blood transfusion, or donate blood volume≥200mL within 1 month prior dosing.
  • Take any clinical trial drugs within 3 months prior dosing;
  • Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A in 14 days before dosing;
  • Addicted to alcohol and tobacco, drinking 14 units of alcohol per week (1 unit =285 mL of beer, or 100mL of wine), or take ≥5 cigarettes;
  • Positive in urine drug test;
  • Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;
  • Anyone who refuse to stop ingesting drinks containing methylxanthine, or grapefruit or grapefruit-containing products from 48 hours before dosing to the end of the study;
  • The investigator believes that the subjects are not eligible to participate in this trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    mild renal impairment

    Drug: Apatinib Mesylate

  • Experimental
    moderate remal impairment

    Drug: Apatinib Mesylate

  • Active comparator
    normal renal impairment

    Drug: Apatinib Mesylate

Interventions

  • All the subjects will be administrated with 250mg apatinib on day 1

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: 0-96 hours

  2. AUC0-t

    Area under the plasma concentration versus time curve from zero to 96h

    Time frame: 0-96 hours

  3. AUC0-∞

    Area under the plasma concentration versus time curve from zero to infinity

    Time frame: 0-96 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2020; primary completion for Jan 2021, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2020
First posted
Jun 4, 2020
StartEst.
Jun 5, 2020
Primary completionEst.
Jan 15, 2021
CompletionEst.
Apr 30, 2021
Last update
Jun 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04414852
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jun 5, 2020 (estimated)
Primary completion
Jan 15, 2021 (estimated)
Completion
Apr 30, 2021 (estimated)
Last update
Jun 4, 2020

Study contacts

Yuya Wang
Contact
wangyuya@hrglobe.cn
13918749176

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion